Be Aware of New Safety Issues With Xeljanz

April 2021

Safety concerns are stacking up with tofacitinib (Xeljanz, Xeljanz XR) for rheumatoid arthritis and other autoimmune diseases.

Xeljanz and other "Janus kinase (JAK) inhibitors" are already linked to blood clots...serious infections...and other issues.

Now experts are warning that Xeljanz may increase the risk of heart attacks and other serious cardiovascular (CV) events. There are also more data that it increases the risk of cancer.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Dispensing Don't Leave Off Key Details in Rx Sigs
COVID-19 Listen for New Questions About COVID-19 Vaccines
COVID-19 Know Which COVID-19 Rxs May Be Too Soon for Prime Time
HIV & AIDS Understand the New INSTI HIV Self Test for Use at Home
Headache Help Aimovig Patients Get Set Up With a Blood Pressure Monitor
Bowel Preps Avoid Mix-Ups With Bowel Preps
Diabetes Stay Alert for Patients With Diabetes Who May Need a Statin
Respiratory & Allergy Watch for Jorveza, a New Med for Eosinophilic Esophagitis
Immunosuppressives Be Aware of New Safety Issues With Xeljanz

Be Aware of New Safety Issues With Xeljanz

Practical advice for a better career, with unlimited access to CE

Table of Contents